GET DAILY SIGNALSBeyondSpring Inc. (BYSI): Tracking Plinabulin's Path in Oncology Development
Key Takeaways
- BYSI is the ticker for BeyondSpring Inc., a clinical-stage biopharmaceutical company developing cancer and immunology therapies.
- The company's lead drug candidate is Plinabulin, a first-in-class agent being studied in late-stage trials for non-small cell lung cancer (NSCLC) and other cancers.
- BeyondSpring has no approved products or meaningful revenue yet; its business model depends on advancing its pipeline through clinical trials and regulatory approval.
- The company operates through two segments: the Plinabulin pipeline and a targeted protein degradation (TPD) platform.
- Investing in BYSI carries significant biotechnology risk, including clinical-trial, regulatory, and financing uncertainty.
Introduction
BeyondSpring Inc. (BYSI) is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for cancers and other diseases with high unmet medical need. Unlike established pharmaceutical firms that sell approved drugs, BeyondSpring is a development-stage company whose financial profile is defined by research and development spending rather than product sales. Investors follow the company primarily for the progress of its lead oncology asset, Plinabulin, and its potential to become a commercially meaningful cancer treatment.
Company Background and History
BeyondSpring was founded in 2010 and is headquartered in Florham Park, New Jersey. The company is listed on the Nasdaq exchange under the ticker BYSI. As a small-cap biotechnology firm, it employs a relatively small team and directs most of its resources toward clinical development and drug discovery rather than commercial operations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company's business model is built around advancing novel drug candidates through the clinical-trial process, with the goal of securing regulatory approvals from agencies such as the U.S. Food and Drug Administration (FDA) and, ultimately, generating revenue through commercialization or partnerships. Because no product has been approved to date, BeyondSpring's revenue has historically been minimal or zero, and the company funds its operations through equity offerings and strategic transactions.
Lead Asset: Plinabulin
Plinabulin is BeyondSpring's lead drug candidate and the primary driver of the company's market position. It is described as a first-in-class GEF-H1 agonist and selective immunomodulating microtubule-binding agent. This mechanism is intended to promote dendritic cell maturation and modulate the tumor microenvironment, potentially enhancing both anti-cancer activity and the body's immune response.
Plinabulin has completed Phase 3 clinical trials in non-small cell lung cancer (NSCLC), a common and difficult-to-treat form of lung cancer. In the DUBLIN-3 study, results published in The Lancet Respiratory Medicine indicated that Plinabulin combined with the chemotherapy drug docetaxel outperformed docetaxel alone in second- and third-line patients with EGFR wild-type NSCLC. The company is now advancing DUBLIN-4, a confirmatory Phase 3 program designed to validate those results in patients whose cancer has progressed after treatment with PD-1/PD-L1 checkpoint inhibitors.
BeyondSpring has also explored Plinabulin for the prevention of chemotherapy-induced neutropenia, a condition involving abnormally low levels of infection-fighting white blood cells, and is investigating its potential use in combination with antibody-drug conjugates (ADCs) and immuno-oncology agents.
Business Segments
BeyondSpring reports its operations through two primary segments. The first is the Plinabulin pipeline, which encompasses the clinical development of its lead oncology asset. The second is a targeted protein degradation (TPD) platform, a drug-discovery approach aimed at creating therapies that selectively remove disease-causing proteins. This platform is associated with the company's SEED Therapeutics subsidiary and represents a longer-term, earlier-stage element of the broader pipeline.
Why Investors Follow BYSI
Investor interest in BYSI is driven largely by the scientific potential of Plinabulin and the size of the oncology market it targets. Lung cancer remains one of the most common and deadly cancers worldwide, creating significant demand for improved treatments, particularly for patients who have progressed after immunotherapy. A successful confirmatory trial and eventual FDA approval could transform the company's financial profile from a pre-revenue developer into a commercial-stage biopharmaceutical business.
The company's intellectual property also contributes to its long-term appeal, with a patent portfolio that extends into the 2030s and potentially beyond in key markets. BeyondSpring's strategy of positioning Plinabulin as a combination agent with widely used therapies broadens the potential commercial opportunity beyond a single indication.
Risks and Important Considerations
Biotechnology companies at BeyondSpring's stage carry substantial risk. Plinabulin is not yet approved, and there is no guarantee that ongoing or future trials will succeed or satisfy regulators. The confirmatory DUBLIN-4 program is a critical milestone, and unfavorable results could significantly affect the company's prospects.
Financing is another central consideration. As a pre-revenue company, BeyondSpring depends on raising capital to fund its research and development, and future equity offerings could dilute existing shareholders. The company also faces competition from larger pharmaceutical firms with greater resources, and its results can be influenced by clinical timelines, regulatory decisions, and macroeconomic conditions affecting access to capital.
My Experience with Tickeron Tools
In my research process, I often rely on Tickeron’s AI Screener to quickly filter biotech names by pipeline stage, volatility, and technical patterns. It allows me to compare opportunities like BYSI against sector peers using customizable criteria such as fundamentals, trends, and AI-generated signals. This helps surface ideas that align with specific risk tolerances without sifting through thousands of listings manually.
Conclusion
BeyondSpring Inc. (BYSI) is a clinical-stage biopharmaceutical company whose identity and valuation are closely tied to a single lead asset, Plinabulin, and its prospects in non-small cell lung cancer and related oncology indications. Its position at the intersection of chemotherapy, immunotherapy, and emerging ADC-based treatments makes it a notable, if speculative, name in the oncology space. For investors, the company represents a classic biotechnology profile: meaningful scientific potential balanced against the inherent uncertainties of clinical development, regulation, and financing.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BYSI in downward trend: 10-day moving average moved below 50-day moving average on October 12, 2026
The 10-day moving average for BYSI crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BYSI moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
BYSI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BYSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
BYSI broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BYSI entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on BYSI as a result. In 74 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for BYSI just turned positive on October 30, 2026. Looking at past instances where BYSI's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Following a +55.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where BYSI advanced for three days, in 174 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.724) is normal, around the industry mean (3.498). P/E Ratio (-3.682) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (31.056) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. BYSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BYSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of cancer therapies
Industry Biotechnology
Advertisement